[Clinical experience with omalizumab in patients with severe asthma. Real-world data].
Omalizumab is a monoclonal antibody that is prescribed in a stepwise addition regimen for the treatment of severe asthma. To report the experience of patients with severe asthma who were given omalizumab in accordance with international guides, in a context of real-world data. Open, analytical, cross-sectional, retrospective, observational clinical study with real-world data. GINA 2006 Asthma Control Scheme was used to evaluate patients, and a questionnaire was used to evaluate patient characteristics, effectiveness, safety, and tolerance to omalizumab. 48 patients were studied, 34 women and 14 men with an average age of 39 years. The average disease duration was 26 years. Average serum IgE was 522 IU. At the beginning of treatment, all patients had uncontrolled asthma; at the end, 69% asthma control was obtained, 19% was partially controlled and 12% unchanged. The changes were observed at seven months on average. Omalizumab is effective and safe for treating severe asthma when applied in accordance with international guidelines for the management of bronchial asthma.